Literature DB >> 26588440

Identification of key active constituents of Buchang Naoxintong capsules with therapeutic effects against ischemic stroke by using an integrative pharmacology-based approach.

Xu Haiyu1, Shi Yang2, Zhang Yanqiong1, Jia Qiang3, Li Defeng1, Zhang Yi1, Liu Feng4, Yang Hongjun1.   

Abstract

Integrative pharmacology has been used to identify the key active constituents (KACs) of Buchang Naoxintong capsules (BNCs), a traditional Chinese medical preparation; this approach involves the evaluation of the content profiles and drug-like properties of the BNC constituents and development of an ingredient-target network. In this study, we used a sensitive analytical method to simultaneously identify and quantify 16 constituents of BNCs. Metabolism of these constituents by gut microbiota and human oral bioavailability were predicted using an in silico approach, followed by construction of networks to analyze the interactions between BNC constituents, their molecular targets, and proteins known to be the molecular targets for Food and Drug Administration-approved colitis medication. Finally, an animal model of ischemic stroke was used to verify the therapeutic effects of the KACs of BNCs. Amygdalin and paeoniflorin were identified as the KACs because they were the 2 most abundant BNC constituents, having appropriate drug-like properties, and produced therapeutic effects against cerebral ischemia. Amygdalin produced an anti-cerebral ischemia effect, likely by interacting with the glucocorticoid receptor (NR3C1) and serpin peptidase inhibitor, clade C (antithrombin), member 1 (SERPINC1). These results form the basis for conducting studies to identify KACs in traditional medicinal preparations; such studies might improve quality control and allow the in vivo evaluation of synergistic interactions between the complex mixtures of compounds.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26588440     DOI: 10.1039/c5mb00460h

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  13 in total

1.  Main active constituent identification in Guanxinjing capsule, a traditional Chinese medicine, for the treatment of coronary heart disease complicated with depression.

Authors:  Yan-Qiong Zhang; Qiu-Yan Guo; Qiu-Yue Li; Wei-Qiong Ren; Shi-Huan Tang; Song-Song Wang; Ri-Xin Liang; De-Feng Li; Yi Zhang; Hai-Yu Xu; Hong-Jun Yang
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

2.  Molecular mechanisms of the analgesic action of Wu-tou Decoction on neuropathic pain in mice revealed using microarray and network analysis.

Authors:  Yan-Qiong Zhang; Chao Wang; Qiu-Yan Guo; Chun-Yan Zhu; Chen Yan; Dan-Ni Sun; Qiong-Hong Xu; Na Lin
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

3.  Investigation of the Multi-Target Mechanism of Guanxin-Shutong Capsule in Cerebrovascular Diseases: A Systems Pharmacology and Experimental Assessment.

Authors:  Juanli Zhang; Jiaxin Zhao; Yang Ma; Wenjun Wang; Shaojie Huang; Chao Guo; Kai Wang; Xiaomei Zhang; Wei Zhang; Aidong Wen; Ming Shi; Yi Ding
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

4.  Therapeutic effects of Euphorbia Pekinensis and Glycyrrhiza glabra on Hepatocellular Carcinoma Ascites Partially Via Regulating the Frk-Arhgdib-Inpp5d-Avpr2-Aqp4 Signal Axis.

Authors:  Yanqiong Zhang; Chen Yan; Yuting Li; Xia Mao; Weiwei Tao; Yuping Tang; Ya Lin; Qiuyan Guo; Jingao Duan; Na Lin
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

5.  Integrated Modules Analysis to Explore the Molecular Mechanisms of Phlegm-Stasis Cementation Syndrome with Ischemic Heart Disease.

Authors:  Wei-Ming Xu; Kuo Yang; Li-Jie Jiang; Jing-Qing Hu; Xue-Zhong Zhou
Journal:  Front Physiol       Date:  2018-01-22       Impact factor: 4.566

6.  Integrated metabolomics and gut microbiome to the effects and mechanisms of naoxintong capsule on type 2 diabetes in rats.

Authors:  Zenghao Yan; Hao Wu; Haokui Zhou; Shuo Chen; Yan He; Weijian Zhang; Taobin Chen; Hongliang Yao; Weiwei Su
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

7.  A Metabonomics Investigation into the Therapeutic Effects of BuChang NaoXinTong Capsules on Reversing the Amino Acid-Protein Interaction Network of Cerebral Ischemia.

Authors:  Jing Xu; Xin Liu; Liyu Luo; Liying Tang; Na Guo; Mengting Liu; Hongmei Li; Fangbo Zhang; Yi Zhang; Defeng Li; Ye Zhao; Hongwei Wu; Hongjun Yang
Journal:  Oxid Med Cell Longev       Date:  2019-03-20       Impact factor: 6.543

Review 8.  Effect of Buyang Huanwu decoction for the rehabilitation of ischemic stroke patients: a meta-analysis of randomized controlled trials.

Authors:  Li Gao; Zhuoran Xiao; Chunhua Jia; Wei Wang
Journal:  Health Qual Life Outcomes       Date:  2021-03-09       Impact factor: 3.186

9.  Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells.

Authors:  Hong Sun; Xiao-Ya Lou; Xiao-Ying Wu; Huan Wang; Qiang Qu; Shen-Lan Tan; Jun-Shan Ruan; Jian Qu; Hui Chen
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

Review 10.  Mitochondrial MPTP: A Novel Target of Ethnomedicine for Stroke Treatment by Apoptosis Inhibition.

Authors:  Yangxin Li; Jiayi Sun; Ruixia Wu; Jinrong Bai; Ya Hou; Yong Zeng; Yi Zhang; Xiaobo Wang; Zhang Wang; Xianli Meng
Journal:  Front Pharmacol       Date:  2020-03-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.